Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Structured physical exercise improves neuropsychiatric symptoms in acute dementia care: a hospital-based RCT.

Fleiner T, Dauth H, Gersie M, Zijlstra W, Haussermann P.

Alzheimers Res Ther. 2017 Aug 29;9(1):68. doi: 10.1186/s13195-017-0289-z.

2.

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.

Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D.

Int J Neuropsychopharmacol. 2017 Jul 1;20(7):519-528. doi: 10.1093/ijnp/pyx012.

3.

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.

Boada M, Anaya F, Ortiz P, Olazarán J, Shua-Haim JR, Obisesan TO, Hernández I, Muñoz J, Buendia M, Alegret M, Lafuente A, Tárraga L, Núñez L, Torres M, Grifols JR, Ferrer I, Lopez OL, Páez A.

J Alzheimers Dis. 2017;56(1):129-143. doi: 10.3233/JAD-160565.

4.

Detecting clinical change with the CDR-FTLD: differences between FTLD and AD dementia.

Mioshi E, Flanagan E, Knopman D.

Int J Geriatr Psychiatry. 2017 Sep;32(9):977-982. doi: 10.1002/gps.4556. Epub 2016 Jul 28.

5.

Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.

Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Gold M, Morimoto BH, Boxer AL; AL-108-231 Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:41-48. doi: 10.1016/j.parkreldis.2016.04.014. Epub 2016 Apr 18.

6.

Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.

Tsai RM, Lobach I, Bang J, Whitwell JL, Senjem ML, Jack CR Jr, Rosen H, Miller B, Boxer AL; AL-108-231 Investigators.

Parkinsonism Relat Disord. 2016 Jul;28:29-35. doi: 10.1016/j.parkreldis.2016.04.006. Epub 2016 Apr 24.

7.

Principal components analysis of agitation outcomes in Alzheimer's disease.

Yesavage JA, Taylor JL, Friedman L, Rosenberg PB, Lazzeroni LC, Leoutsakos JS, Kinoshita LM, Perlow MJ, Munro CA, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A; CitAD Research Group.

J Psychiatr Res. 2016 Aug;79:4-7. doi: 10.1016/j.jpsychires.2016.04.004. Epub 2016 Apr 16.

8.

Outcome measures for Parkinson's disease dementia: a systematic review.

Holden SK, Jones WE, Baker KA, Boersma IM, Kluger BM.

Mov Disord Clin Pract. 2016 Jan-Feb;3(1):9-18. Epub 2015 Sep 16.

9.

Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.

Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, Ichise M, Manly J, Devanand DP, Bagiella E.

J Alzheimers Dis. 2016;51(2):501-14. doi: 10.3233/JAD-150493.

10.
11.

Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

Aisen PS.

J Prev Alzheimers Dis. 2015;2(2):82-84. No abstract available.

12.

Parkinson's Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort.

Lawton M, Baig F, Rolinski M, Ruffman C, Nithi K, May MT, Ben-Shlomo Y, Hu MT.

J Parkinsons Dis. 2015;5(2):269-79. doi: 10.3233/JPD-140523.

13.

COSMOS--improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial.

Husebo BS, Flo E, Aarsland D, Selbaek G, Testad I, Gulla C, Aasmul I, Ballard C.

Implement Sci. 2015 Sep 15;10:131. doi: 10.1186/s13012-015-0310-5.

14.

The Effect of Lipoic Acid Therapy on Cognitive Functioning in Patients with Alzheimer's Disease.

Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C, Ermio C, De Bartolo M, Mauro G, Bosco D.

J Neurodegener Dis. 2013;2013:454253. doi: 10.1155/2013/454253. Epub 2013 Mar 30.

15.

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.

Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG; CitAD Research Group.

Int Psychogeriatr. 2015 Dec;27(12):2059-67. doi: 10.1017/S1041610215001106. Epub 2015 Aug 25.

16.

Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.

Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D; CitAD Research Group.

J Geriatr Psychiatry Neurol. 2016 Mar;29(2):59-64. doi: 10.1177/0891988715601735. Epub 2015 Aug 23.

17.

Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis.

Matsunaga S, Kishi T, Yasue I, Iwata N.

Int J Neuropsychopharmacol. 2015 Jul 28;19(2). pii: pyv086. doi: 10.1093/ijnp/pyv086. Review.

18.

THE QUICK DEMENTIA RATING SYSTEM (QDRS): A RAPID DEMENTIA STAGING TOOL.

Galvin JE.

Alzheimers Dement (Amst). 2015 Jun 1;1(2):249-259.

20.

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.

Atri A, Hendrix SB, Pejović V, Hofbauer RK, Edwards J, Molinuevo JL, Graham SM.

Alzheimers Res Ther. 2015 May 18;7(1):28. doi: 10.1186/s13195-015-0109-2. eCollection 2015.

Supplemental Content

Support Center